While research by Schuberth et al. showed limited anti‐tumoral effects of anti‐FAP‐α CAR T cells and significant “on‐target, off‐tumor” toxicity, anti‐FAP‐α CAR‐T‐cell therapy has shown promising effectiveness in numerous preclinical models of various solid tumors.124, 125. This evidence concerns the gene FAP and neoplasm.